## VTR: Ventas, Inc. - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_20 -2.5% below STRENGTH zone (4.0-10.0%); PEG 1.74 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Ventas, Inc. (NYSE:VTR) Declares $0.48 Quarterly Dividend**
- Source: MarketBeat | 20251211T153638 | Neutral | Relevance: 100%
- Ventas, Inc. (NYSE:VTR) has declared a quarterly dividend of $0.48 per share, payable on January 15th to shareholders of record by December 31st, implying an annualized yield of 2.5%. While the current payout ratio of 249.4% is elevated, analysts project future earnings per share of $3.69 next year, which would bring the future payout ratio to about 52%. The stock traded down 1.4% to $76.64, with recent insider selling reported by CEO Peter J. Bulgarelli and CEO Debra A. Cafaro.

**2. Key Reasons to Add Ventas Stock to Your Portfolio Right Now**
- Source: Finviz | 20251211T150900 | Bullish | Relevance: 100%
- Ventas, Inc. (VTR) is a strong healthcare REIT poised for growth due to its diverse portfolio, focus on the aging population and outpatient medical trends, and accretive investments in research. The company also maintains a healthy balance sheet, making it an attractive addition to investor portfolios. Analysts are positive, and the stock is outperforming its industry, suggesting further growth potential.

**3. Key Reasons to Add Ventas Stock to Your Portfolio Right Now**
- Source: TradingView | 20251211T140911 | Bullish | Relevance: 100%
- Ventas, Inc. (VTR) is a strong stock pick due to its diverse portfolio of healthcare real estate assets, which positioned it to benefit from rising healthcare spending and an aging population. The company's focus on its outpatient medical and research (OM&R) portfolio and accretive investments in research further solidify its growth prospects. Additionally, Ventas maintains a healthy balance sheet, suggesting continued financial strength and potential for stock growth.

**4. Ventas declares quarterly dividend of $0.48 per share**
- Source: Investing.com India | 20251210T221058 | Bullish | Relevance: 100%
- Ventas, Inc. (NYSE:VTR) announced a quarterly dividend of $0.48 per common share, payable on January 15, 2026, to stockholders of record as of December 31, 2025. The real estate investment trust specializes in properties for aging populations and has consistently paid dividends for 27 consecutive years. This announcement follows positive third-quarter earnings, a successful senior notes offering, and a raised price target from Cantor Fitzgerald.

**5. Ventas declares quarterly dividend of $0.48 per share By Investing.com**
- Source: Investing.com Australia | 20251210T220901 | Somewhat-Bullish | Relevance: 100%
- Ventas, Inc. (NYSE:VTR) announced a quarterly dividend of $0.48 per common share, payable on January 15, 2026, to stockholders of record as of December 31, 2025. The real estate investment trust focuses on properties for aging populations and has consistently paid dividends for 27 years. This announcement follows strong third-quarter 2025 earnings and a successful senior notes offering.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Keybanc | $85 | $70 | +21% |
| 2025-11-25 | Wells Fargo | $88 | $80 | +10% |
| 2025-11-13 | Scotiabank | $80 | $74 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Keybanc | main | Overweight |
| 2025-11-25 | Wells Fargo | main | Overweight |
| 2025-11-13 | Scotiabank | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 17 ($4.24M) |
| Sells | 13 ($23.19M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 15.7% (+2.5%)
- JPMORGAN CHASE & CO: 12.7% (+102.6%)
- Blackrock Inc.: 11.1% (+2.6%)
- State Street Corpora: 6.2% (+3.3%)
- FMR, LLC: 5.7% (+12.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.7% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.74 elevated, pricing in significant growth expectations. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.6B |
| Beta | 0.79 |
| 52W Range | $56.68 - $81.89 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.74 |
| Forward P/E | 137.8 |
| Current P/E | 288.4 |
| YoY Growth | 109.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 0.2% to -2.5% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-0.62), momentum weakening. RSI neutral at 50. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.47% (CS: 18) | Weak |
| RSI_14 | 49.6 | Neutral |
| MACD Histogram | -0.62 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 1.041x | Above |
| vs SMA200 | 1.135x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.86
- **Stop Loss:** $75.08 (3.6% risk)
- **Target:** $80.64 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 431
- **Position Value:** $33,557.66
- **Portfolio %:** 33.56%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-11 (Est: $0.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.05 | $0.12 | +141.9% |
| 2025Q2 | $0.14 | $0.15 | +10.4% |
| 2025Q1 | $0.07 | $0.10 | +35.8% |
| 2024Q4 | $0.05 | $0.13 | +156.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*